Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Blood (2019) 134 (18): 1498–1509.

https://doi.org/10.1182/blood.2019000428

Published: 2019

Includes: Supplemental data

Journal Articles

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Blood (2018) 132 (Supplement 1): 577.

https://doi.org/10.1182/blood-2018-99-111946

Published: 2018

Journal Articles

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Blood (2018) 132 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2018-99-111929

Published: 2018

Journal Articles

Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 4206.

https://doi.org/10.1182/blood.V130.Suppl_1.4206.4206

Published: 2017

Journal Articles

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

Ellen K Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Javier Pinilla-Ibarz, MD PhD, Michael W. Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, MD, Michael R. Savona, MD, Ilva Dautaj, MS, Das Purkayastha, Karen Habucky, PhD, Michael J. Mauro, MD

Blood (2017) 130 (Supplement 1): 2875.

https://doi.org/10.1182/blood.V130.Suppl_1.2875.2875

Published: 2017

Journal Articles

Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 321.

https://doi.org/10.1182/blood.V130.Suppl_1.321.321

Published: 2017

Journal Articles

CNS Relapse in Diffuse Large B-Cell Lymphoma Patients with Oral Cavity and Bone Marrow Involvement-Experience from an Inner City Hospital

Surabhi Pathak, MBBS, Romy Jose Thekkekara, MBBS, Jibran Ahmed, MD MBBS, Paula Kovarik, MD, Rosalind Catchatourian, MD

Blood (2016) 128 (22): 5409.

https://doi.org/10.1182/blood.V128.22.5409.5409

Published: 2016

Journal Articles

Prognostic Significance of Bone Marrow Involvement in Hodgkin Lymphoma

Ankit Mangla, MBBS, MD, Muhammad Umair Mushtaq, MD, Rohit Kumar, MD, Nikki Agarwal, MD, Sibgha Gull Chaudhary, MBBS, Rosalind Catchatourian, MD

Blood (2016) 128 (22): 5370.

https://doi.org/10.1182/blood.V128.22.5370.5370

Published: 2016

Journal Articles

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Jesus G. Berdeja, MD, Michael Heinrich, Shaker Dakhil, MD FACP, Stuart L. Goldberg, MD, Martha Wadleigh, MD, Rosalind Catchatourian, MD, Philip Kuriakose, MD, Jorge E. Cortes, MD, Jerald P. Radich, David A. Rizzieri, MD, Gaetano Bonifacio, MD, Ilva Dautaj, Ghulam Warsi, PhD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4048.

https://doi.org/10.1182/blood.V126.23.4048.4048

Published: 2015

Journal Articles

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Ellen K. Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Michael W Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, Michael R. Savona, MD, Ghulam Warsi, PhD, Carole S. Paley, Ilva Dautaj, Felice P. Lin, PharmD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4050.

https://doi.org/10.1182/blood.V126.23.4050.4050

Published: 2015

Journal Articles

Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update

Michael J. Mauro, MD, Shaker Dakhil, MD FACP, Jorge E. Cortes, MD, David A. Rizzieri, MD, Christopher H Keir, MD, Sandy Yi, MS, Michael C. Heinrich, MD, Stuart L. Goldberg, MD, Rosalind Catchatourian, MD, Philip Kuriakose, MD, Jerald P Radich, MD

Blood (2014) 124 (21): 1796.

https://doi.org/10.1182/blood.V124.21.1796.1796

Published: 2014

Journal Articles

Staging Bone Marrow Biopsy Does Not Alter Management in Patients with Hodgkin Lymphoma and May Not be Necessary:a 10yr Single Institutional Retrospective Review of Patients with Hodgkin Lymphoma with Bone Marrow Involvement 2004-2013

Moyosore M. Suleiman, MD, Ankit Mangla, MD, Hussein Hamad, Romy Thekekkara, Kalid Adab, MD, Rosalind Catchatourian, MD

Blood (2014) 124 (21): 5361.

https://doi.org/10.1182/blood.V124.21.5361.5361

Published: 2014

Journal Articles

Efficacy of Novel Agents in Multiple Myeloma in Comparison to Autologous Stem Cell Transplant: A Retrospective Study in a Single Inner City Institution

Tareq Braik, MD, Dayra Avila, MD, Shivi Jain, MD, Manila Gaddh, MD, Barabara Yim, PharmD, Peter Ruestow, MPH, Shylendra B Sreenivasappa, MD, Shweta Gupta, MD, Sylvia Velinova, MD, Paul G. Rubinstein, MD, Margaret Telfer, MD, Mousami Shah, MD, Thomas Lad, Rosalind Catchatourian, MD

Blood (2011) 118 (21): 5118.

https://doi.org/10.1182/blood.V118.21.5118.5118

Published: 2011

Journal Articles

Clinical Significance of Positive Red Blood Cell Antibody Screen with Inconclusive Antibody Identification

Shweta Gupta, MD, Prantesh Jain, MD, Harsha v Poola, MD, Sumedha Dhar, MD, Manila Gaddh, MD, Paul G. Rubinstein, MD, Tareq Braik, MD, Rosalind Catchatourian, MD, Margaret Clare Telfer, MD, FACP, Ram Kakaiya, MD

Blood (2011) 118 (21): 4340.

https://doi.org/10.1182/blood.V118.21.4340.4340

Published: 2011

Journal Articles

A Three Year Experience at An Inner City Safety-Net Hospital with Immune Thrombocytopenic Purpura (ITP)

Harsha V Poola, MD, Manila Gaddh, MD, Samuel N. Ofori, MD, Moushmi Shah, MD, Mohammed A. Kassem, MD, Augustin Haidau, MD, Rosalind Catchatourian, MD, Margaret Telfer, MD

Blood (2010) 116 (21): 4684.

https://doi.org/10.1182/blood.V116.21.4684.4684

Published: 2010

Journal Articles

Response of Patients with Aggressive Non Hodgkin's Gastro Intestinal Tract Lymphoma to Upfront Rituximab Based Chemotherapy: A Single Institution Experience.

Bety Ciobanu, MD, Shylendra B Sreenivasappa, MD, Mousami Shah, Barbara Yim, Pharm, D, Rosalind Catchatourian, MD

Blood (2009) 114 (22): 4791.

https://doi.org/10.1182/blood.V114.22.4791.4791

Published: 2009

Journal Articles

Efficacy of RICE as Second Line Chemotherapy in Transplant Ineligible Patients with Diffuse Large B Cell Lymphoma: a Single Institution Experience.

Mousami Shah, Shylendra B Sreenivasappa, MD, Barbara Yim, Pharm, D, Bety Ciobanu, MD, Rosalind Catchatourian, MD

Blood (2009) 114 (22): 4757.

https://doi.org/10.1182/blood.V114.22.4757.4757

Published: 2009

Journal Articles

Response to Anti D immunoglobulin in Adults with Chronic Immune Thrombocytopenic Purpura in a Minority Cohort with Long Term Follow up.

Shylendra B Sreenivasappa, MD, Tareq Braik, MD, Sonia Sandhu, MD, Barbara Yim, Pharm, D, Rosalind Catchatourian, MD

Blood (2009) 114 (22): 4465.

https://doi.org/10.1182/blood.V114.22.4465.4465

Published: 2009

Journal Articles

Clinical Presentation, Risk Profiles and Outcomes of Chemotherapy without Bone Marrow Transplant in a Cohort of Minority Patients with Acute Lymphoblastic Leukemia from a Public Health Hospital

Bety Ciobanu, MD, Shylendra B Sreenivasappa, MD, Tracy Smiley, RN, Barbara Yim, Pharm.D, Paula Kovarik, MD, Mousami Shah, MD, Rafid Kouz, MD, Samuel Ofori, MD, Margaret Clare Telfer, MD, Rosalind Catchatourian, MD

Blood (2008) 112 (11): 3958.

https://doi.org/10.1182/blood.V112.11.3958.3958

Published: 2008

NARROW

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

CNS Relapse in Diffuse Large B-Cell Lymphoma Patients with Oral Cavity and Bone Marrow Involvement-Experience from an Inner City Hospital

Prognostic Significance of Bone Marrow Involvement in Hodgkin Lymphoma

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update

Staging Bone Marrow Biopsy Does Not Alter Management in Patients with Hodgkin Lymphoma and May Not be Necessary:a 10yr Single Institutional Retrospective Review of Patients with Hodgkin Lymphoma with Bone Marrow Involvement 2004-2013

Efficacy of Novel Agents in Multiple Myeloma in Comparison to Autologous Stem Cell Transplant: A Retrospective Study in a Single Inner City Institution

Clinical Significance of Positive Red Blood Cell Antibody Screen with Inconclusive Antibody Identification

A Three Year Experience at An Inner City Safety-Net Hospital with Immune Thrombocytopenic Purpura (ITP)

Response of Patients with Aggressive Non Hodgkin's Gastro Intestinal Tract Lymphoma to Upfront Rituximab Based Chemotherapy: A Single Institution Experience.

Efficacy of RICE as Second Line Chemotherapy in Transplant Ineligible Patients with Diffuse Large B Cell Lymphoma: a Single Institution Experience.

Response to Anti D immunoglobulin in Adults with Chronic Immune Thrombocytopenic Purpura in a Minority Cohort with Long Term Follow up.

Clinical Presentation, Risk Profiles and Outcomes of Chemotherapy without Bone Marrow Transplant in a Cohort of Minority Patients with Acute Lymphoblastic Leukemia from a Public Health Hospital

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only